Association of Immune-Related Adverse Events with Efficacy in Patients With Small Cell Lung Cancer: a Second Analysis of Phase 3 IMpower133 Randomized Clinical Trials
Xia, S.
Show abstract
IntroductionWhile immune-related adverse events (irAEs) are associated with improved outcomes for patients with non-small cell lung cancer (NSCLC), this relationship is unelucidated in small cell lung cancer (SCLC), where predictive biomarkers are critically needed.To evaluate the association between irAEs and overall survival (OS) in patients with extensive-stage SCLC (ES-SCLC) receiving first-line chemoimmunotherapy. MethodsThis secondary analysis utilized individual participant data from the IMpower133 study, a global, phase 3 randomized clinical trial that enrolled patients with previously untreated ES-SCLC receiving atezolizumab plus chemotherapy. ResultsThe development of irAEs was not associated with improved OS. Patients who experienced an irAE had a median OS of 10.0 months compared to 9.77 months for patients without irAEs, a non-significant difference. ConclusionsThis finding challenges the established paradigm in NSCLC, underscores the distinct immunobiology of SCLC, and cautions against the extrapolation of biomarkers across thoracic malignancies, highlighting the urgent need for disease-specific biomarker discovery.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- KRAS mutations impact clinical outcome in metastatic non-small cell lung cancer 95%
- Machine learning for prediction of immunotherapy efficacy in non-small cell lung cancer from simple clinical and biological data 93%
- Circulating Low Density Neutrophils Are Associated with Resistance to First-Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer 93%
Similar papers in this journal
- Insulin-like Growth Factor 1 Receptor Expression Correlates with Programmed Death Ligand 1 Expression and Poor Survival in Non-small Cell Lung Cancer 92%
- Survival benefits of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma: evidence from a SEER-based retrospective cohort study 91%
- Survival benefit of adjuvant therapy following neoadjuvant therapy in patients with resected esophageal cancer: a retrospective cohort study 91%
Similar papers in this journal
- Efficacy of PD-(L)1 blockade monotherapy compared to PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study 90%
- Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events 89%
- Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration ofinflammatory immune cells in EGFR mutant lung tumors 89%
Similar papers in this journal
- Construction and Validation of a Nomogram Based on the Log Odds of Positive Lymph Based on the Log Odds of Positive Lymph Nodes to Predict the Prognosis of Lung Neuroendocrine Tumors 92%
- Definition of a new blood cell count (BCT) score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of 4 multicenter clinical trials 91%
- Dissected subgroups predict the risk of recurrence of stage II colorectal cancer and select rational treatment 90%
Similar papers in this journal
- Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden 92%
- MMP2 As An Independent Prognostic Stratifier In Oral Cavity Cancers 89%
- Non-Small Cell Lung Cancer Patients Treated with Anti-PD1 Immunotherapy Show Distinct Microbial Signatures and Metabolic Pathways According to Clinical Outcomes 88%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.